Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year revenue guidance by $1.5 billion to be in the range of $60 billion to $62 billion; reported EPS guidance raised to be in the range of $20.85...
Related Questions
How does the 38% revenue increase compare to peers such as Novo Nordisk, Pfizer, and Eli Lilly's own historical growth rates?
How will the raised 2025 revenue guidance of $60‑$62 billion affect LLY's valuation multiples?
How does the guidance upgrade affect the relative position of LLY within the biotech/ pharma sector index?
What are the profit margin implications of the increased revenue—will gross and operating margins sustain or improve?
What regulatory, pricing, or payer risk factors could threaten the projected growth of Zepbond and Mounjaro?
What is the expected impact on LLY's price‑to‑earnings multiple and forward earnings estimates?
What are the key drivers behind the increase in EPS guidance to $20.85–$21.20 per share, and how sensitive is this to cost inflation or R&D spend?
What are the market expectations for the price trajectory of Zepbound and Mounjo (‘Mounjaro’) sales momentum?
How will the Q2 results affect short‑term technical levels and trader sentiment (e.g., momentum, short‑interest) for LLY stock?
How will the expected FY2025 revenue range of $60‑$62 billion influence analyst consensus and target price revisions?